Tendinopathy is a tendon disorder characterized by tendon deterioration that often leads to tendon rupture, and is associated with pain, swelling and impaired performance. There is currently no cure for tendinopathy. Therefore, there is an urgent need for effective treatments for tendinopathy. The parent award is focused on testing the TenoGen, the product to be developed, exerts a therapeutic effect in mitigating tendinopathy pathology and relieving tendinopathy-related pain and symptoms with no or minimal adverse effects. The purpose of this supplement project is to provide support for an underrepresented researcher to participate and contribute to the R&D of TenoGen within the scope of the parent study. The supplement study will focus on establishing the transcriptome profile of TenoGen treatment using state-of-the-art transcriptomic RNA sequencing (RNA-seq) and bioinformatics technologies. Successful completion of the proposed supplement project is expected to not only provide additional data to accelerate for the R&D and commercialization of TenoGen, but also provide valuable support and an unique opportunity for the candidate?s career development. 1
Tendinopathy is a common chronic tendon disorder, characterized by pain and impaired performance, and currently has no cure or effective treatments. The goal of the parent study is to test the hypothesis that the product to be developed exerts a therapeutic effect in mitigating tendinopathy pathology and relieving tendinopathy-related pain and symptoms with no or minimal adverse effects. The proposed supplement project will provide critical support and an unique training opportunity for a promising underrepresented candidate to carry out additional studies within the scope of the parent award which is expected to significantly accelerate the commercialization of a biologic for the treatment of tendinopathy.